Amylyx Pharmaceuticals Enters Underwriting Agreement for Public Offering

On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share. The firm shares are part of the offering, with the possibility of an additional 2,571,428 shares […]

Leave a Reply

Your email address will not be published.

Previous post Greggs (LON:GRG) Shares Down 14.5% – What’s Next?
Next post Bioxytran (OTCMKTS:BIXT) to Release Cancer Preprint Revealing Potential Immunotherapy EnhancementOn January 10, 2025, Bioxytran Inc., a clinical-stage biotechnology company focused on developing oral and intravenous drugs for various conditions, anno